The double upgrade from a mid-tier firm combined with strong upward EPS revisions and elevated short interest creates a tactical setup for a squeeze. Traders should watch for follow-through above $410 as confirmation of the bullish catalyst.
Price Chart
Executive Summary
Oppenheimer double-upgraded Intuitive Surgical (ISRG) from Perform to Outperform on August 12, 2026, setting a $500 price target. The call is contrarian relative to a recent HSBC downgrade to Hold on July 30, but aligns with the broader bullish consensus where 28 of 40 analysts rate the stock Buy or Strong Buy. Oppenheimer's 52% accuracy on 1,808 calls and 3.6% average return place it near the middle of the coverage universe. The $500 target sits above the $477 mean and $483 median, implying 24.6% upside from the $401.23 close. EPS revisions have been strongly positive over the past 30 days, with 20 upward revisions for the current quarter and 23 for the current year. Insider selling over the past two weeks, including a $151,600 sale by director Gary Loeb, partially offsets the bullish signal. The upgrade is a meaningful contrarian call from a firm with moderate accuracy, warranting attention.
Impact Score
Consensus & Targets
The consensus is heavily bullish: 12 Strong Buy, 16 Buy, 11 Hold, 1 Sell, 0 Strong Sell — 70% Buy/Strong Buy. The direction is clearly positive, with only one analyst bearish.
Current price: $401.23. Mean target: $477.25 (upside 18.9%), median: $483 (upside 20.4%), high: $685 (upside 70.7%), low: $324 (downside -19.2%). Oppenheimer's $500 target is above the mean and median, in the upper third of the range.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-12 | Oppenheimer | upgrade | Outperform | $500.00 |
| 2026-07-30 | HSBC | downgrade | Hold | $931.00 |
| 2026-07-17 | Raymond James | maintain | Outperform | $483.00 |
| 2026-07-17 | Piper Sandler | reiterate | Overweight | $470.00 |
| 2026-07-17 | JP Morgan | maintain | Overweight | $450.00 |
| 2026-07-17 | Mizuho | maintain | Neutral | $400.00 |
| 2026-07-17 | Wells Fargo | maintain | Overweight | $487.00 |
| 2026-07-17 | TD Cowen | maintain | Buy | $485.00 |
| 2026-07-17 | Evercore ISI Group | maintain | In-Line | $375.00 |
| 2026-07-17 | RBC Capital | maintain | Outperform | $575.00 |
30-day analyst activity: 1 upgrade (Oppenheimer) and 1 downgrade (HSBC). EPS revisions are strongly positive: current quarter saw 20 upward vs 2 downward revisions in 30 days; current year saw 23 upward vs 0 downward. Estimates are being revised higher across all periods.
Firm Track Record — Oppenheimer
Oppenheimer accuracy: 52% on 1808 calls | avg return: 3.6%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Morgan Stanley | 100% | 3/3 | 9.9% | top tier |
| Baird | 100% | 5/5 | 12.1% | top tier |
| Stifel | 100% | 4/4 | 11.7% | top tier |
| BTIG | 91% | 10/11 | 14.5% | top tier |
| Evercore ISI Group | 86% | 6/7 | 9.9% | top tier |
| Piper Sandler | 75% | 6/8 | 7.9% | top tier |
| RBC Capital | 71% | 5/7 | 6.3% | top tier |
| JP Morgan | 67% | 2/3 | 4.8% | top tier |
| Barclays | 67% | 2/3 | 11.3% | top tier |
| Truist Securities | 64% | 7/11 | 3.6% | top tier |
Oppenheimer has a 52% accuracy rate on 1,808 calls with a 3.6% average return — middle of the pack. Top-tier firms on ISRG include Morgan Stanley (100% on 3 calls, +9.9% avg return), Baird (100% on 5, +12.1%), and BTIG (91% on 11, +14.5%). The worst performers are Raymond James (33% on 3, -0.9%) and Wells Fargo (40% on 5, +0.2%).
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $2.64 | $2.53 — $2.76 | $2.9B | ↑3 ↓0 |
| +1q | $2.84 | $2.72 — $3.02 | $3.2B | ↑2 ↓0 |
| 0y | $10.79 | $10.66 — $11.08 | $11.8B | ↑0 ↓0 |
| +1y | $12.07 | $11.28 — $12.72 | $13.2B | ↑4 ↓0 |
Cross-Platform Signals
Insider trades show selling: director Gary Loeb sold $151,600 on Aug 10, and EVP Amy Ladd sold $151,600 on Aug 10 and $28,303 on Aug 11. No congressional trades. Institutional activity is mixed: First Trust Advisors doubled its position (+262.7%), while Assenagon trimmed (-42.7%). Short interest is elevated at 55.1% of TRF volume, suggesting bearish positioning that could fuel a squeeze on positive news.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 11d ago | ANALYST-UPGRADE | $414.52 $422.06 | ▲ +1.82% | ▲ +1.72% | $426.70 (+2.94%) |
Sep 16, 2026 4w ago | Insider Cluster | $382.29 $398.30 | ▲ +4.19% | ▲ +1.62% | $426.70 (+11.62%) |
Aug 19, 2026 8w ago | Insider Cluster | $374.48 $367.07 | ▼ −1.98% | ▼ −3.09% | $426.70 (+13.94%) |
Aug 13, 2026 9w ago | Court Ruling | $401.27 $374.48 | ▲ +6.68% | ▲ +4.71% | $426.70 (−6.34%) |
Aug 12, 2026 9w ago | ANALYST-UPGRADE | $401.27 $397.72 | ▼ −0.88% | ▼ −0.44% | $426.70 (+6.34%) |
Aug 12, 2026 9w ago | Insider Cluster | $401.27 $397.72 | ▼ −0.88% | ▼ −0.44% | $426.70 (+6.34%) |
Aug 11, 2026 9w ago | Insider Cluster | $401.27 $397.72 | ▼ −0.88% | ▼ −0.44% | $426.70 (+6.34%) |
Jul 30, 2026 11w ago | ANALYST-DOWNGRADE | $352.97 $373.71 | ▲ +5.88% | ▲ +2.25% | $426.70 (+20.89%) |
Jul 16, 2026 13w ago | Press Release | $345.42 $332.02 | ▼ −3.88% | ▼ −3.19% | $426.70 (+23.53%) |
Jul 9, 2026 14w ago | ANALYST-UPGRADE | $411.55 $402.33 | ▼ −2.24% | ▼ −2.11% | $426.70 (+3.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access